Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.38%430.140.0%$5769.95m
BNTXBioNTech SE -5.53%333.480.0%$994.80m
NVAXNovavax, Inc. -3.55%248.1679.4%$950.95m
SNSSSunesis Pharmaceuticals, Inc. -0.46%8.650.7%$604.67m
AMGNAmgen, Inc. -0.67%213.611.4%$550.92m
GILDGilead Sciences, Inc. -0.70%71.191.0%$455.28m
REGNRegeneron Pharmaceuticals, Inc. -1.18%638.902.7%$418.56m
TECHBio-Techne Corp. 0.37%538.884.5%$356.85m
ILMNIllumina, Inc. -0.09%432.823.5%$356.73m
BIIBBiogen, Inc. -0.51%291.711.7%$309.48m
VRTXVertex Pharmaceuticals, Inc. -0.80%183.611.9%$245.25m
ISEEIVERIC bio, Inc. 0.86%16.370.0%$193.25m
DVAXDynavax Technologies Corp. 1.17%19.835.7%$156.65m
LIFEaTyr Pharma, Inc. -17.87%10.252.1%$156.36m
BGNEBeiGene Ltd. -1.53%379.521.3%$144.32m

Company Profile

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.